MedPath

Fluticasone furoate

Generic Name
Fluticasone furoate
Brand Names
Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
Drug Type
Small Molecule
Chemical Formula
C27H29F3O6S
CAS Number
397864-44-7
Unique Ingredient Identifier
JS86977WNV
Background

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.

Indication

Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulmonary disease (COPD) and for the treatment of asthma in patients ≥18 years old for the vilanterol-umeclidinium-fluticasone product and ≥5 years old for the vilanterol-fluticasone product.

Fluticasone furoate is available over the counter as a nasal spray for the symptomatic treatment of hay fever and other upper respiratory allergies in patients ≥2 years old.

Associated Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
Clinical Trials
Related News

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: albuterol/salbutamol
First Posted Date
2011-09-12
Last Posted Date
2017-01-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
238
Registration Number
NCT01431950
Locations
🇷🇺

GSK Investigational Site, Pyatigorsk, Russian Federation

Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Matching placebo
First Posted Date
2011-04-11
Last Posted Date
2017-03-23
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
27
Registration Number
NCT01332292
Locations
🇺🇸

GSK Investigational Site, Medford, Oregon, United States

Rhinitis, Cognition and Driving Performance

Not Applicable
Completed
Conditions
Driving Ability
Cognition
Seasonal Allergic Rhinitis
Interventions
Drug: placebo
First Posted Date
2011-03-18
Last Posted Date
2013-11-08
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
22
Registration Number
NCT01318681
Locations
🇳🇱

Maastricht University, Maastricht, Limburg, Netherlands

Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease

Phase 3
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Other: Placebo
First Posted Date
2011-03-14
Last Posted Date
2018-08-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16568
Registration Number
NCT01313676
Locations
🇻🇳

GSK Investigational Site, Hue, Vietnam

Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects

Phase 1
Completed
Conditions
Asthma
Interventions
Drug: GW642444
First Posted Date
2011-02-18
Last Posted Date
2017-06-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16
Registration Number
NCT01299558
Locations
🇦🇺

GSK Investigational Site, Randwick, New South Wales, Australia

A Phase-IV, Open-label Study to Evaluate Safety/Tolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis

Phase 4
Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
First Posted Date
2011-01-05
Last Posted Date
2014-08-06
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
60
Registration Number
NCT01270958
Locations
🇻🇳

GSK Investigational Site, Ha Noi, Vietnam

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
First Posted Date
2010-09-13
Last Posted Date
2017-08-14
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
540
Registration Number
NCT01199757

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2010-07-12
Last Posted Date
2017-11-09
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
350
Registration Number
NCT01159912
Locations
🇷🇴

GSK Investigational Site, Iasi, Romania

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: FF/GW642444M
Drug: GW642444M
Drug: Placebo
First Posted Date
2010-05-24
Last Posted Date
2017-01-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
27
Registration Number
NCT01128595
Locations
🇸🇪

GSK Investigational Site, Lund, Sweden

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: FF/Vilanterol (VI; GW642444M)
Drug: Placebo
First Posted Date
2010-05-24
Last Posted Date
2017-01-18
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
52
Registration Number
NCT01128569
Locations
🇬🇧

GSK Investigational Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy